| To view this email as a web page, click here.
|
 |
| First-Line Extensive-Stage Small Cell Lung Cancer: |
| Examining the New Role of Combination Chemotherapy and Immunotherapy |
| |
| Thursday, December 3, 2020 • 8 pm ET |
| |
 |
| |
| |
 |
 |
 |
MODERATOR
Kathryn Gold, MD
Associate professor and vice chief
Division of Hematology and
Oncology
UC San Diego Moores Cancer
Cancer
San Diego, California |
SPEAKER
Taofeek Owonikoko, MD
Professor and vice chair for
faculty development
Hematology and Medical Oncology
Emory University
Atlanta, GA |
SPEAKER
Konstantinos Leventakos, MD, PhD
Oncologist
Mayo Clinic
Rochester, MN |
| |
|
| |
|
| Our expert panel will discuss with you how to navigate the new role of I/O therapy in combination with chemotherapy for the first-line treatment of ES-SCLC and answer your questions surrounding how to use this approach in clinical practice. |
| |
| |
| Attend this special event to have a better understanding of: |
- Characteristics of small cell lung cancer
How SCLC and NSCLC are differentiated in clinical practice
- The need for rapid treatment response to ES-SCLC
- The role of combination chemotherapy + I/O therapy in first-line ES-SCLC
|
- Clinical trials for I/O + chemotherapy combinations
- Standard first-line approach
- Patient involvement in treatment during the pandemic
|
|
